Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).

恩扎鲁胺 医学 前列腺癌 内科学 临床终点 不利影响 肿瘤科 癌症 雄激素受体 临床试验
作者
Daniel J. George,Nasreen Khan,Niculae Constantinovici,Javeed Khan,Guifang Chen,Julie Xu,Jorge Ortíz,Alicia K. Morgans
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (6_suppl): 332-332 被引量:1
标识
DOI:10.1200/jco.2023.41.6_suppl.332
摘要

332 Background: Second-generation androgen receptor inhibitors (ARIs) are the preferred treatment for patients (pts) with non-metastatic castration-resistant prostate cancer (nmCRPC). In this setting, an important therapeutic goal is to minimize adverse events (AEs) and prolong time on ARI treatment. This is the first study to assess real-world (RW) utilization and outcomes of all currently available ARIs, darolutamide (daro), enzalutamide (enza), and apalutamide (apa) in pts with nmCRPC. Methods: DEAR (NCT05362149) is a retrospective observational chart review using electronic medical records from the Precision Point Specialty network of US urology practices. Eligibility criteria included nmCRPC diagnosis, no previous treatment with a novel hormonal agent, and ARI treatment initiation for the first time from August 2019 to March 2022. Pts were classified into 3 cohorts based on the first prescribed ARI in the nmCRPC stage. We present an interim report including the primary composite endpoint (DIS/MET): proportion of pts who discontinued initial ARI treatment (DIS) or progressed to metastasis (MET); and secondary endpoints: time to DIS/MET and underlying reasons. Results: In total, 666 pts were included (daro/enza/apa, n=276/280/110). The proportion of pts starting treatment with daro increased during the study period relative to enza or apa, which declined or remained stable, respectively. Median age (80/79/80 years), White race (68%/69%/74%) and median PSA doubling time (6.7/6.0/7.8 months) at baseline were similar in the daro/enza/apa cohorts, respectively. Median length of follow-up was similar. Fewer pts had a DIS/MET event during the study in the daro cohort (35.9%), compared with enza or apa (52.1%/50.9%); this trend was seen within 6 to 18 months after ARI start. Median time to DIS/MET was 33.4/20.8/18.5 months for daro/enza/apa, respectively. Most common reasons for DIS/MET in the daro/enza/apa cohorts were AEs (8.3%/15.0%/12.7%), death (3.3%/5.4%/2.7%), and MET (14.9%/22.9%/18.2%). Conclusions: This RW study in the US shows that, despite similar baseline characteristics, fewer nmCRPC pts treated with daro had DIS/MET (especially due to AEs/MET) versus enza and apa, and the time to this event was longer in the daro cohort. These findings may be attributed to daro being a structurally distinct ARI with low potential for blood–brain barrier penetration. [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
桐桐的应助被做错了范采纳,获得10
1秒前
初景发布了新的文献求助10
1秒前
xwy发布了新的文献求助10
1秒前
senger发布了新的文献求助10
1秒前
梨花诗完成签到,获得积分20
1秒前
xing_xing的应助被吱吱吱采纳,获得20
2秒前
YHY发布了新的文献求助10
2秒前
幸运星完成签到,获得积分10
2秒前
syvshc的应助被小黑球采纳,获得10
2秒前
2秒前
阿九发布了新的文献求助10
3秒前
风中的小鸽子完成签到 ,获得积分10
3秒前
万能图书馆的应助被Code_king采纳,获得10
3秒前
3秒前
思源的应助被XXQ采纳,获得10
3秒前
qeyqor完成签到,获得积分10
4秒前
4秒前
科研通AI65的应助被cgl155410采纳,获得20
4秒前
慕青的应助被称心学姐采纳,获得10
4秒前
lpp完成签到,获得积分10
5秒前
5秒前
芷云完成签到,获得积分10
5秒前
乐乐的应助被hh采纳,获得10
5秒前
5秒前
5秒前
5秒前
YIXIAO关注了科研通微信公众号
6秒前
脑洞疼的应助被333采纳,获得10
6秒前
甜甜大炮发布了新的文献求助10
7秒前
bkagyin的应助被疯狂的枫叶采纳,获得10
7秒前
ding的应助被xiaohai1466采纳,获得10
7秒前
7秒前
CICI完成签到,获得积分10
7秒前
9秒前
四季西瓜完成签到,获得积分10
9秒前
难过飞绿发布了新的文献求助10
9秒前
科研通AI2S的应助被Code_king采纳,获得10
9秒前
不爱喝酒给南极星人的求助进行了留言
10秒前
DHW完成签到 ,获得积分10
10秒前
Austin发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176102
求助须知:如何正确求助?哪些是违规求助? 9567588
关于积分的说明 21793477
捐赠科研通 7770603
什么是DOI,文献DOI怎么找? 3431969
关于科研通互助平台的介绍 2556294
邀请新用户注册赠送积分活动 2477522